- Search for Research Summaries, Reviews, and Reports
- EPC Project
Related Products for this Topic
- Executive Summary Jan. 17, 2007
Research Review - Final – Jan. 17, 2007
Efficacy and Comparative Effectiveness of Off-Label Use of Atypical Antipsychotics
- Final Report (PDF) 551 kB
- Report Appendixes (PDF) 3.3 MB
- Web Version (NLM Site)
- Help with Viewers, Players, and Plug-ins
Archived: This report has been updated.
People using assistive technology may not be able to fully access information in these files. For additional assistance, please contact us.
Aripiprazole, olanzapine, quetiapine, risperidone, and ziprasidone are atypical antipsychotics approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia and bipolar disorder. These drugs have been studied for off-label use in the following conditions: dementia and severe geriatric agitation, depression, obsessive-compulsive disorder, posttraumatic stress disorder, and personality disorders. The atypicals have also been studied for the management of Tourette's syndrome and autism in children. The purpose of this report is to review the scientific evidence on the safety and effectiveness of such off-label uses.